PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform

PacBio (NASDAQ:PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment.

The collaboration addresses a growing bottleneck in biomedical AI: increasingly powerful models require biological data with greater depth, context and scale. Long-read sequencing can reveal complex genetic variants, structural changes, methylation information, and full-length RNA transcripts that are difficult to capture with short-read approaches, offering richer insights into disease biology. Yet, processing these large, complex datasets and integrating them with clinical data for model training remains fragmented, unscalable and largely bespoke. PacBio and Verily Health intend to connect those steps, making rich genomic data more accessible and usable to power the next generation of biomedical AI applications. Verily Pre already supports population-scale biomedical research, while Workbench serves more than 20,000 researchers and has supported more than 700 publications. And because PacBio HiFi whole-genome sequencing workflows already run end-to-end within the Verily Pre environment, it provides an existing and robust technical foundation for the multi-year collaboration.